We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Dicerna Pharmaceuticals Inc | NASDAQ:DRNA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 38.22 | 42.07 | 38.22 | 0 | 00:00:00 |
From Feb 2020 to Feb 2025
By Colin Kellaher
Shares of Dicerna Pharmaceuticals Inc. rose nearly 80% on Thursday after the biopharmaceutical company agreed to be acquired by collaboration partner Novo Nordisk A/S for about $3.3 billion.
Danish drugmaker Novo will pay $38.25 a share in cash for Dicerna, a roughly 80% premium to Wednesday's closing price of $21.28 for the Cambridge, Mass., company.
Dicerna and Novo in late 2019 struck a deal to develop novel therapies for liver-related cardio-metabolic diseases in a collaboration potentially worth billions of dollars to Dicerna.
Novo on Thursday said it expects to initiate clinical development of the first investigational RNAi therapeutic to emerge from the collaboration next year.
Dicerna shares were recently up 78.6% to $38.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2021 11:32 ET (16:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Dicerna Pharmaceuticals Chart |
1 Month Dicerna Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
